Group 1: Financial Performance - In 2024, the company achieved revenue of CNY 2.549 billion, with a net profit of CNY 127 million, representing a decline of 11.98% and 59.44% year-on-year respectively [5] - In Q1 2025, the company reported revenue of CNY 510 million and a net profit of CNY 24 million, down 17.22% and 80.09% year-on-year [5] - The revenue from agency products in 2024 was CNY 612 million, while revenue from self-developed products was CNY 1.913 billion, with a growth of 1.75% in self-developed product sales [5] Group 2: Product Performance - In 2024, self-developed immunological reagents generated CNY 1.029 billion in revenue, an increase of 8.04% year-on-year; biochemical reagents generated CNY 499 million, a decrease of 12.53%; and clinical testing reagents generated CNY 214 million, an increase of 21.70% [5] - In Q1 2025, self-developed product sales revenue was CNY 407 million, down 3.23% year-on-year, with immunological reagents at CNY 210 million (down 4.20%), biochemical reagents at CNY 95 million (down 26%), and clinical testing reagents at CNY 49 million (stable) [6] Group 3: Profitability and Cost Management - The overall gross margin for 2024 was approximately 55%, with a decline of about 1 percentage point in Q1 2025 compared to Q1 2024 [7] - The gross margin for self-developed products decreased by 4.76 percentage points, while the average gross margin for self-developed reagents remained stable at around 80% [9] - In 2024, operational expenses were effectively controlled, with sales expenses down about 1%, management expenses down about 10%, and financial expenses down about 30% [10] Group 4: Business Strategy and Market Trends - The company is focusing on the separation of agency business and enhancing self-developed products, with a strategic shift towards automated laboratory solutions [5] - The impact of national policies such as medical insurance reform and centralized procurement is expected to gradually manifest, with an estimated 20%-30% impact on overall testing volumes in the terminal market [14] - The company plans to limit the proportion of agency products to below 10% in the future, as the revenue from agency products has significantly decreased [20] Group 5: International Business and Future Outlook - In 2024, overseas sales revenue reached CNY 160 million, a year-on-year increase of nearly 60%, with Q1 2025 overseas sales revenue close to CNY 50 million, up 90% [15] - The company is optimistic about future overseas sales and plans to establish a new overseas sales subsidiary in 2025 [15] - The company anticipates that the next two to three years will be critical for industry development, with a focus on enhancing market share in both domestic and international markets [21]

迈克生物股份有限公司主要从事体外诊断产品研发、生产、销售和服务。公司主营产品包括自产和代理 诊断试剂及诊断仪器。公司产品具备国际一流的品质，是国内IVD企业最早建立量值溯源系统的公司， 也是国际医学量值溯源体系国际检验医学溯源联合委员会(JCTLM)中首家中国企业代表。 最新一期业绩显示，2025年一季报，公司实现营业收入5.10亿元，同比-17.22%；净利润2397.96万元， 同比-80.09%，销售毛利率56.76%。 5月6日，迈克生物今日收盘11.54元，上涨1.50%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到232.94倍，总市值70.68亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均48.90倍，行业中值36.41倍，迈克生物排 名第117位。 截至2025年一季报，共有4家机构持仓迈克生物，其中其他2家、QFII1家、基金1家，合计持股数 2542.85万股，持股市值3.31亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)117迈克生物232.9455.741.1170.68亿行业平均 48.9047.004.53103.78亿行业中值36. ...

证券代码:300463 证券简称:迈克生物 公告编号:2025-037 迈克生物股份有限公司 关于持股 5%以上股东部分股份质押及解除质押的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈 述或者重大遗漏。 迈克生物股份有限公司（以下简称"公司"）于近日收到持股 5%以上股东郭雷先生的通 知，获悉郭雷先生将其持有的部分公司股份办理了质押及解除质押手续，现将具体情况公告如 下： 一、股东股份质押及解除质押的基本情况 （一）股东股份解除质押的基本情况 2025 年 4 月 16 日，公司持股 5%以上股东郭雷先生将其已质押的股份 6,200,000 股办理了 解除质押手续，情况如下： | 股东 | 是否为第一 | | 解除质押股 | 本次解除质 | 占公司 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 姓名 | | 大股东及一 | 数（股） | 押占其所持 | 总股本 | | 质押起始日 | | 质押到期日 | | ...

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 13.54 [7][8]. Core Views - The company's revenue for 2024 is reported at RMB 2549 million, a year-over-year decline of 12.0%, primarily due to short-term industry policy disruptions and adjustments in the agency business, alongside goodwill impairment [1]. - The core business revenue showed stable growth, with self-developed product revenue reaching RMB 1913 million in 2024, reflecting a year-over-year increase of 1.8% [1]. - The company is expected to enhance its competitive edge in core self-developed businesses and achieve long-term positive development [1]. Summary by Sections Main Business Performance - The company achieved revenue of RMB 2549 million and net profit attributable to the parent company of RMB 127 million in 2024, with a significant decline in net profit by 59.4% year-over-year [1]. - In Q1 2025, the company reported revenue of RMB 510 million, a decrease of 17.2% year-over-year, attributed to ongoing adjustments in sales strategies and increased promotional investments [1]. Chemical Luminescence Segment - Revenue from chemical luminescence reagents in 2024 was RMB 1029 million, showing an 8.0% year-over-year growth, indicating increasing market recognition [2]. - The company expects to sell nearly 2000 new chemical luminescence instruments in 2025, which will positively impact reagent consumption at hospital terminals [2]. Other Business Segments - The biochemical segment reported revenue of RMB 499 million in 2024, down 13.5% year-over-year, likely due to price adjustments following provincial alliance procurement [3]. - The clinical inspection segment saw a revenue increase of 21.8% year-over-year, reaching RMB 214 million, driven by successful promotion of clinical inspection equipment [3]. - The agency business continued to weaken, with revenue dropping 37.6% year-over-year to RMB 612 million [3]. Profit Forecast and Valuation - The earnings per share (EPS) forecast for 2025 is adjusted to RMB 0.49, reflecting a 44% downward revision compared to previous estimates [4]. - The target price of RMB 13.54 is based on a sum-of-the-parts (SOTP) valuation method, applying price-to-earnings (PE) ratios of 28x for self-developed products and 24x for agency products [4].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of 13.54 RMB [7][8]. Core Views - The company's revenue for 2024 is reported at 2.549 billion RMB, a year-over-year decline of 12.0%, primarily due to short-term industry policy disruptions and adjustments in the agency business [1]. - The core business revenue showed stable growth, with self-produced product revenue reaching 1.913 billion RMB in 2024, an increase of 1.8% year-over-year [1]. - The company is expected to enhance its competitive edge in core self-operated businesses and achieve long-term positive development [1]. Summary by Sections Main Business Performance - In 2024, the company achieved revenue of 2.549 billion RMB, with a net profit attributable to the parent company of 126.81 million RMB, reflecting a significant decline of 59.4% year-over-year [6]. - The first quarter of 2025 saw revenue of 510 million RMB, a decrease of 17.2% year-over-year, attributed to ongoing adjustments in sales strategies and increased promotional investments [1]. Chemical Luminescence Segment - The revenue from chemical luminescence reagents in 2024 was 1.029 billion RMB, marking an 8.0% year-over-year increase, indicating growing market recognition [2]. - The company expects to sell nearly 2,000 new chemical luminescence instruments in 2025, which will positively impact reagent consumption at hospital terminals [2]. Other Business Segments - The biochemical segment reported revenue of 499 million RMB in 2024, down 13.5% year-over-year, likely due to price adjustments following provincial alliance procurement [3]. - The clinical inspection segment experienced rapid growth, with revenue of 214 million RMB, up 21.8% year-over-year, driven by successful equipment promotion [3]. - The agency business saw a significant decline in revenue, down 37.6% year-over-year to 612 million RMB, as its contribution continues to diminish [3]. Profit Forecast and Valuation - The earnings per share (EPS) forecast for 2025 is adjusted to 0.49 RMB, reflecting a 44% downward revision compared to previous estimates [4]. - The target price of 13.54 RMB is based on a sum-of-the-parts (SOTP) valuation method, applying price-to-earnings (PE) ratios of 28x for self-produced products and 24x for agency products [4][12].

Core Insights - The company reported a significant decline in both revenue and net profit for the year 2024, indicating substantial challenges faced during the period [1][2][3] Financial Performance - Revenue for 2024 was 2.549 billion yuan, down 11.98% from 2.896 billion yuan in the previous year, with the core in vitro diagnostic products segment also experiencing a similar decline [2] - Net profit attributable to shareholders was 127 million yuan, a sharp decrease of 59.44% compared to 313 million yuan in the previous year, primarily due to reduced revenue and a goodwill impairment loss of 94 million yuan [3] - The net profit excluding non-recurring items was 138 million yuan, down 56.20% from 316 million yuan, indicating challenges in the core business profitability [4] - Basic earnings per share fell to 0.2091 yuan, a decrease of 59.29% from 0.5136 yuan, reflecting a decline in shareholder returns [5] Expense Analysis - Sales expenses slightly decreased to 647 million yuan, a minor reduction of 0.86%, suggesting inefficiencies in marketing expenditures [6] - Management expenses decreased by 10.37% to 165 million yuan, indicating effective internal cost control measures [7] - Financial expenses were reduced by 29.50% to 16.43 million yuan, reflecting improved debt management [8] Cash Flow Analysis - Net cash flow from operating activities decreased by 29.70% to 634 million yuan, indicating potential issues in sales collections [11] - Net cash outflow from investing activities increased by 34.67% to -677 million yuan, primarily due to increased investments in the IVD Tianfu Industrial Park [12] - Net cash outflow from financing activities increased by 17.00% to -127 million yuan, highlighting pressures from dividend distributions [13] R&D and Innovation - R&D expenses remained stable at 323 million yuan, reflecting the company's commitment to innovation [10] - R&D investment for 2024 was 419 million yuan, accounting for 21.91% of self-owned product revenue, indicating a focus on product development [14] - The number of R&D personnel increased from 1,172 to 1,221, enhancing the company's innovation capabilities [15]

证券代码：300463 证券简称：迈克生物 公告编号：2025-022 迈克生物股份有限公司 关于披露《2024 年年度报告》的提示性公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 2025 年 4 月 28 日，迈克生物股份有限公司（以下简称"公司"）召开第六届董事会第三 次会议，审议通过了《关于公司 2024 年度报告全文及其摘要的议案》。 为使广大投资者全面了解公司的经营、财务状况，公司《2024 年年度报告》《2024 年年 度报告摘要》于 2025 年 4 月 29 日在中国证监会指定的创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）上披露，敬请投资者注意查阅。 特此公告。 迈克生物股份有限公司 董事会 二〇二五年四月二十九日 第 1 页 共 1 页 ...

证券代码：300463 证券简称：迈克生物 公告编号：2025-031 迈克生物股份有限公司 关于 2025 年度公司向金融机构申请授信额度 及项下业务的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 迈克生物股份有限公司（以下简称"迈克生物"、"公司"）于2025年4月28日召开第六届董 事会第三次会议及第六届监事会第三次会议，分别审议通过了《关于2025年度公司向金融机构 申请综合授信额度及项下业务的议案》，具体情况如下： 一、申请综合授信额度的情况 根据公司生产经营的需要，为满足公司生产经营的资金需求，保障公司稳健运营，2025 年 度公司拟向金融机构申请不超过人民币 27.7 亿元的综合授信额度及项下业务，其中包含以位 于成都市高新区百川路 16 号的土地房产继续为向中国银行股份有限公司成都蜀都支行申请的 敞口授信额度及项下业务提供抵押担保不超过人民币 3.5 亿元，该授信额度包括新增授信及原 有授信的展期或者续约，授信项下业务包含但不限于流动资金贷款、各类保函、信用证、应收 账款保理、贸易融资、银行承兑汇票、商业承兑汇票、置换其他机构贷款等，授信 ...

证券代码：300463 证券简称：迈克生物 公告编号：2025-034 迈克生物股份有限公司 关于召开2024年年度股东大会的通知 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 2025年4月28日，迈克生物股份有限公司（以下简称"公司"）第六届董事会第三次会议 审议通过了《关于召开2024年年度股东大会的议案》，拟定于2025年5月19日（星期一） 14:00召开2024年年度股东大会，本次股东大会将采取现场投票和网络投票相结合的方式。 现将有关事项通知如下： 一、本次会议的基本情况 1、股东大会届次：2024年年度股东大会 2、会议召集人：公司董事会 3、会议召开的合规性：本次股东大会的召开符合有关法律、行政法规、部门规章、规 范性文件和《公司章程》的有关规定，公司第六届董事会第三次会议已经审议通过召开本 次股东大会的议案。 4、会议召开的日期、时间： （1）现场会议召开时间为：2025年5月19日（星期一）14:00 （2）网络投票时间为：通过深圳证券交易所系统进行网络投票的具体时间为：2025年 5月19日上午9:15-9:25，9:30-11:30， ...

独立董事 2024 年度述职报告 各位股东及股东代表： 作为迈克生物股份有限公司（以下简称"公司"）第五届董事会独立董事，2024 年度，本人严 格按照《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以 下简称"《证券法》"）、《上市公司独立董事管理办法》（以下简称"《管理办法》"）、《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》（以下简称"《创业 板上市公司规范运作》"）等相关法律法规的规范要求，以及《公司章程》《独立董事工作制度》 的相关制度赋予的权利和义务，诚信、勤勉、尽责、忠实地履行职责，及时了解公司的生产经营 及发展情况，积极出席相关会议，对各项议案进行认真审议，发挥专业特长，为公司经营发展提 出合理化建议，有效维护了公司整体利益和全体股东的合法权益。现就本人 2024 年度履行独立董 事职责情况汇报如下： 一、本人基本情况、任职资格及独立性说明 本人，廖振中先生，1977 年出生，中国国籍，无境外永久居留权，博士学历。拥有深厚的法 律知识和丰富的法律从业经验，曾任成都传媒集团新闻实业公司独立董事、成都兴媒嘉年华投资 有限公司外部董事、宝盈 ...